{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T14:45:17Z","timestamp":1702305917096},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,8,20]],"date-time":"2022-08-20T00:00:00Z","timestamp":1660953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,20]],"date-time":"2022-08-20T00:00:00Z","timestamp":1660953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008678","name":"Universit\u00e4t Leipzig","doi-asserted-by":"crossref"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Autologous stem cell transplantation (ASCT) is the standard treatment for younger patients with newly diagnosed multiple myeloma (MM). However, due to restrictive exclusion criteria, more than half of eligible patients are usually excluded from transplant studies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This retrospective monocentric analysis included 540 patients with MM who received an ASCT between 1996 and 2019.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Up to 2005, induction therapy consisted mainly of conventional chemotherapies, e.g. vincristine\/doxorubicin\/dexamethasone (VAD). In the following years, the triple-combinations based on bortezomib coupled with doxorubicin\/dexamethasone (PAD), melphalan\/prednisolone (VMP), cyclophposphamide\/dexamethasone (VCD) or bendamustine\/prednisolone (BPV) became the most popular treatment options. A progressive improvement in PFS was observed in patients treated with the two current induction therapies BPV (47\u00a0months) or VCD (54\u00a0months) compared to VAD (35\u00a0months, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.03), PAD (39\u00a0months, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01 and VMP (36\u00a0months, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01). However, there was no significant difference in median OS (VAD 78, PAD 74, VMP 72, BPV 80\u00a0months and VCD not reached). In our analysis, we also included 139 patients who do fulfill at least one of the exclusion criteria for most phase 3 transplant studies (POEMS\/amyloidosis\/plasma cell leukemia, eGFR\u2009&lt;\u200940\u00a0mL\/min, severe cardiac dysfunction or poor general condition). Outcome for these patients was not significantly inferior compared to patients who met the inclusion criteria for most of the transplant studies with PFS of 36 vs 41\u00a0months (<jats:italic>p<\/jats:italic>\u2009=\u20090.78) and OS of 78 vs 79\u00a0months (<jats:italic>p<\/jats:italic>\u2009=\u20090.34).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our real-world data in unselected pts also stress the substantial value of ASCT during the first-line treatment of younger MM pts.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00432-022-04184-x","type":"journal-article","created":{"date-parts":[[2022,8,20]],"date-time":"2022-08-20T17:02:29Z","timestamp":1661014949000},"page":"3739-3752","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of the changing landscape of induction therapy prior to autologous stem cell transplantation in 540 newly diagnosed myeloma patients: a retrospective real-world study"],"prefix":"10.1007","volume":"149","author":[{"ORCID":"http:\/\/orcid.org\/0000-0001-5433-8750","authenticated-orcid":false,"given":"Song-Yau","family":"Wang","sequence":"first","affiliation":[]},{"given":"Tanja","family":"Holzhey","sequence":"additional","affiliation":[]},{"given":"Simone","family":"Heyn","sequence":"additional","affiliation":[]},{"given":"Thomas","family":"Zehrfeld","sequence":"additional","affiliation":[]},{"given":"Susann","family":"Fricke","sequence":"additional","affiliation":[]},{"given":"Franz Albert","family":"Hoffmann","sequence":"additional","affiliation":[]},{"given":"Cornelia","family":"Becker","sequence":"additional","affiliation":[]},{"given":"Leanthe","family":"Braunert","sequence":"additional","affiliation":[]},{"given":"Thomas","family":"Edelmann","sequence":"additional","affiliation":[]},{"given":"Inessa","family":"Paulenz","sequence":"additional","affiliation":[]},{"given":"Marcus","family":"Hitzschke","sequence":"additional","affiliation":[]},{"given":"Franziska","family":"Flade","sequence":"additional","affiliation":[]},{"given":"Andreas","family":"Schwarzer","sequence":"additional","affiliation":[]},{"given":"Klaus","family":"Fenchel","sequence":"additional","affiliation":[]},{"given":"Georg-Nikolaus","family":"Franke","sequence":"additional","affiliation":[]},{"given":"Vladan","family":"Vucinic","sequence":"additional","affiliation":[]},{"given":"Madlen","family":"Jentzsch","sequence":"additional","affiliation":[]},{"given":"Sebastian","family":"Schwind","sequence":"additional","affiliation":[]},{"given":"Saskia","family":"Hell","sequence":"additional","affiliation":[]},{"given":"Donata","family":"Backhaus","sequence":"additional","affiliation":[]},{"given":"Thoralf","family":"Lange","sequence":"additional","affiliation":[]},{"given":"Dietger","family":"Niederwieser","sequence":"additional","affiliation":[]},{"given":"Markus","family":"Scholz","sequence":"additional","affiliation":[]},{"given":"Uwe","family":"Platzbecker","sequence":"additional","affiliation":[]},{"given":"Wolfram","family":"P\u00f6nisch","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2022,8,20]]},"reference":[{"key":"4184_CR1","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1056\/NEJM199607113350204","volume":"335","author":"M Attal","year":"1996","unstructured":"Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Fran\u00e7ais du My\u00e9lome. N Engl J Med 335:91\u201397. https:\/\/doi.org\/10.1056\/NEJM199607113350204","journal-title":"N Engl J Med"},{"key":"4184_CR2","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","volume":"376","author":"M Attal","year":"2017","unstructured":"Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, Arnulf B, Macro M, Belhadj K, Garderet L, Roussel M, Payen C, Mathiot C, Fermand JP, Meuleman N, Rollet S, Maglio ME, Zeytoonjian AA, Weller EA, Munshi N, Anderson KC, Richardson PG, Facon T, Avet-Loiseau H, Harousseau JL, Moreau P, IFM 2009 Study (2017) Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med 376:1311\u20131320. https:\/\/doi.org\/10.1056\/NEJMoa1611750","journal-title":"N Engl J Med"},{"key":"4184_CR3","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1200\/JCO.2005.04.5807","volume":"24","author":"B Barlogie","year":"2006","unstructured":"Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD, McCoy J, Moore DF Jr, Dakhil SR, Lanier KS, Chapman RA, Cromer JN, Salmon SE, Durie B, Crowley JC (2006) Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 24:929\u2013936. https:\/\/doi.org\/10.1200\/JCO.2005.04.5807","journal-title":"J Clin Oncol"},{"key":"4184_CR4","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1200\/JCO.2010.32.7312","volume":"29","author":"B Bj\u00f6rkstrand","year":"2011","unstructured":"Bj\u00f6rkstrand B, Iacobelli S, Hegenbart U, Gruber A, Greinix H, Volin L, Narni F, Musto P, Beksac M, Bosi A, Milone G, Corradini P, Goldschmidt H, de Witte T, Morris C, Niederwieser D, Gahrton G (2011) Tandem autologous\/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. J Clin Oncol 29:3016\u20133622. https:\/\/doi.org\/10.1200\/JCO.2010.32.7312","journal-title":"J Clin Oncol"},{"key":"4184_CR5","doi-asserted-by":"publisher","first-page":"3755","DOI":"10.1182\/blood-2005-03-1301","volume":"106","author":"J Blad\u00e9","year":"2005","unstructured":"Blad\u00e9 J, Rosi\u00f1ol L, Sureda A, Ribera JM, D\u00edaz-Mediavilla J, Garc\u00eda-Lara\u00f1a J, Mateos MV, Palomera L, Fern\u00e1ndez-Calvo J, Mart\u00ed JM, Giraldo P, Carbonell F, Call\u00eds M, Trujillo J, Gardella S, Moro MJ, Barez A, Soler A, Font L, Fontanillas M, San Miguel J, Programa para elEstudio de la Terap\u00e9uticaenHemopat\u00edaMaligna (PETHEMA) (2005) High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 106:3755\u20133759. https:\/\/doi.org\/10.1182\/blood-2005-03-1301","journal-title":"Blood"},{"key":"4184_CR6","doi-asserted-by":"publisher","first-page":"506","DOI":"10.3324\/haematol.2017.178103","volume":"103","author":"CH Blimark","year":"2018","unstructured":"Blimark CH, Turesson I, Genell A, Ahlberg L, Bj\u00f6rkstrand B, Carlson K, Forsberg K, Juliusson G, Linder O, Mellqvist UH, Nahi H, Kristinsson SY, Swedish Myeloma Registry (2018) Outcome and survival of myeloma patients diagnosed 2008\u20132015. Real-world data on 4904 patients from the Swedish Myeloma Registry. Haematologica 103:506\u2013513. https:\/\/doi.org\/10.3324\/haematol.2017.178103","journal-title":"Haematologica"},{"key":"4184_CR7","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","volume":"376","author":"M Cavo","year":"2010","unstructured":"Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M, Di Raimondo F, Crippa C, Zamagni E, Palumbo A, Offidani M, Corradini P, Narni F, Spadano A, Pescosta N, Deliliers GL, Ledda A, Cellini C, Caravita T, Tosi P, Baccarani M, GIMEMA Italian Myeloma Network (2010) Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 376:2075\u20132085. https:\/\/doi.org\/10.1016\/S0140-6736(10)61424-9","journal-title":"Lancet"},{"key":"4184_CR8","doi-asserted-by":"publisher","first-page":"6063","DOI":"10.1182\/blood-2011-02-297325","volume":"117","author":"M Cavo","year":"2011","unstructured":"Cavo M, Rajkumar SV, Palumbo A, Moreau P, Orlowski R, Blad\u00e9 J, Sezer O, Ludwig H, Dimopoulos MA, Attal M, Sonneveld P, Boccadoro M, Anderson KC, Richardson PG, Bensinger W, Johnsen HE, Kroeger N, Gahrton G, Bergsagel PL, Vesole DH, Einsele H, Jagannath S, Niesvizky R, Durie BG, San Miguel J, Lonial S, International Myeloma Working Group (2011) International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood 117:6063\u20136073. https:\/\/doi.org\/10.1182\/blood-2011-02-297325","journal-title":"Blood"},{"key":"4184_CR9","doi-asserted-by":"publisher","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","volume":"7","author":"M Cavo","year":"2020","unstructured":"Cavo M, Gay F, Beksac M, Pantani L, Petrucci MT, Dimopoulos MA, Dozza L, van der Holt B, Zweegman S, Oliva S, van der Velden VHJ, Zamagni E, Palumbo GA, Patriarca F, Montefusco V, Galli M, Maisnar V, Gamberi B, Hansson M, Belotti A, Pour L, Ypma P, Grasso M, Croockewit A, Ballanti S, Offidani M, Vincelli ID, Zambello R, Liberati AM, Andersen NF, Broijl A, Troia R, Pascarella A, Benevolo G, Levin MD, Bos G, Ludwig H, Aquino S, Morelli AM, Wu KL, Boersma R, Hajek R, Durian M, von dem Borne PA, Caravita di Toritto T, Zander T, Driessen C, Specchia G, Waage A, Gimsing P, Mellqvist UH, van Marwijk KM, Minnema M, Mandigers C, Cafro AM, Palmas A, Carvalho S, Spencer A, Boccadoro M, Sonneveld P (2020) Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02\/HO95): a multicentre, randomised, open-label, phase 3 study. Lancet Haematol 7:e456\u2013e468. https:\/\/doi.org\/10.1016\/S2352-3026(20)30099-5","journal-title":"Lancet Haematol"},{"key":"4184_CR10","doi-asserted-by":"publisher","first-page":"4976","DOI":"10.1200\/JCO.2010.30.8791","volume":"28","author":"MA Dimopoulos","year":"2010","unstructured":"Dimopoulos MA, Terpos E, Chanan-Khan A, Leung N, Ludwig H, Jagannath S, Niesvizky R, Giralt S, Fermand JP, Blad\u00e9 J, Comenzo RL, Sezer O, Palumbo A, Harousseau JL, Richardson PG, Barlogie B, Anderson KC, Sonneveld P, Tosi P, Cavo M, Rajkumar SV, Durie BG, San MJ (2010) Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol 28:4976\u20134984. https:\/\/doi.org\/10.1200\/JCO.2010.30.8791","journal-title":"J Clin Oncol"},{"key":"4184_CR11","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BG Durie","year":"2006","unstructured":"Durie BG, Harousseau JL, Miguel JS, Blad\u00e9 J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro M, Cavo M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV, International Myeloma Working Group (2006) International uniform response criteria for multiple myeloma. Leukemia 20:1467\u20131473. https:\/\/doi.org\/10.1038\/sj.leu.2404284","journal-title":"Leukemia"},{"key":"4184_CR12","doi-asserted-by":"publisher","first-page":"3131","DOI":"10.1182\/blood.V92.9.3131","volume":"92","author":"JP Fermand","year":"1998","unstructured":"Fermand JP, Ravaud P, Chevret S, Divine M, Leblond V, Belanger C, Macro M, Pertuiset E, Dreyfus F, Mariette X, Boccacio C, Brouet JC (1998) High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 92:3131\u20133136","journal-title":"Blood"},{"key":"4184_CR13","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/leu.2017.211","volume":"32","author":"H Goldschmidt","year":"2018","unstructured":"Goldschmidt H, Lokhorst HM, Mai EK, van der Holt B, Blau IW, Zweegman S, Weisel KC, Vellenga E, Pfreundschuh M, Kersten MJ, Scheid C, Croockewit S, Raymakers R, Hose D, Potamianou A, Jauch A, Hillengass J, Stevens-Kroef M, Raab MS, Broijl A, Lindemann HW, Bos GMJ, Brossart P, van Marwijk KM, Ypma P, Duehrsen U, Schaafsma RM, Bertsch U, Hielscher T, Jarari L, Salwender HJ, Sonneveld P (2018) Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65\/GMMG-HD4 trial. Leukemia 32:383\u2013390. https:\/\/doi.org\/10.1038\/leu.2017.211","journal-title":"Leukemia"},{"key":"4184_CR14","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1038\/s41375-020-0724-1","volume":"34","author":"H Goldschmidt","year":"2020","unstructured":"Goldschmidt H, Mai EK, D\u00fcrig J, Scheid C, Weisel KC, Kunz C, Bertsch U, Hielscher T, Merz M, Munder M, Lindemann HW, H\u00fcgle-D\u00f6rr B, Tichy D, Giesen N, Hose D, Seckinger A, Huhn S, Luntz S, Jauch A, Elmaagacli A, Rabold B, Fuhrmann S, Brossart P, Goerner M, Bernhard H, Hoffmann M, Hillengass J, Raab MS, Blau IW, H\u00e4nel M, Salwender HJ, German-speaking Myeloma Multicenter Group (GMMG) (2020) Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial. Leukemia 34:1853\u20131865. https:\/\/doi.org\/10.1038\/s41375-020-0724-1","journal-title":"Leukemia"},{"key":"4184_CR15","doi-asserted-by":"publisher","first-page":"4621","DOI":"10.1200\/JCO.2009.27.9158","volume":"28","author":"JL Harousseau","year":"2010","unstructured":"Harousseau JL, Attal M, Avet-Loiseau H, Marit G, Caillot D, Mohty M, Lenain P, Hulin C, Facon T, Casassus P, Michallet M, Maisonneuve H, Benboubker L, Maloisel F, Petillon MO, Webb I, Mathiot C, Moreau P (2010) Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005\u201301 phase III trial. J Clin Oncol 28:4621\u20134629. https:\/\/doi.org\/10.1200\/JCO.2009.27.9158","journal-title":"J Clin Oncol"},{"key":"4184_CR16","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1007\/s00432-020-03504-3","volume":"147","author":"T Holzhey","year":"2021","unstructured":"Holzhey T, P\u00f6nisch W, Wang SY, Holzvogt M, Holzvogt B, Andrea M, Zehrfeld T, Hammerschmidt D, Hoffmann FA, Becker C, Schwarzer A, Schwarz M, Sch\u00f6nfelder-Fricke U, Edelmann T, Braunert L, Franke GN, Jentzsch M, Schwind S, Bill M, Grimm J, Remane Y, Platzbecker U, Scholz M (2021) Prognostic impact of rapid reduction of involved free light chains in multiple myeloma patients under first-line treatment with bendamustine, prednisone, and bortezomib (BPV). J Cancer Res Clin Oncol 147:2349\u20132359. https:\/\/doi.org\/10.1007\/s00432-020-03504-3","journal-title":"J Cancer Res Clin Oncol"},{"key":"4184_CR17","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/s41375-018-0272-0","volume":"33","author":"TW Klausen","year":"2019","unstructured":"Klausen TW, Gregersen H, Abildgaard N, Andersen NF, Fr\u00f8lund UC, Gimsing P, Helleberg C, Vangsted AJ (2019) The majority of newly diagnosed myeloma patients do not fulfill the inclusion criteria in clinical phase III trials. Leukemia 33:546\u2013549. https:\/\/doi.org\/10.1038\/s41375-018-0272-0","journal-title":"Leukemia"},{"key":"4184_CR18","unstructured":"Robert Koch-Institut, Gesellschaft der Epidemiologischen Krebsregister. In: Deutschland EV 12. Auflage, Korrigierte Fassung vom 17.08.2020, Krebs in Deutschland 2015\/2016, Berlin"},{"key":"4184_CR19","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.bbmt.2006.09.010","volume":"13","author":"J Koreth","year":"2007","unstructured":"Koreth J, Cutler CS, Djulbegovic B, Behl R, Schlossman RL, Munshi NC, Richardson PG, Anderson KC, Soiffer RJ, Alyea EP 3rd (2007) High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant 13:183\u2013196. https:\/\/doi.org\/10.1016\/j.bbmt.2006.09.010","journal-title":"Biol Blood Marrow Transplant"},{"key":"4184_CR20","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/leu.2013.313","volume":"28","author":"SK Kumar","year":"2014","unstructured":"Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, Kapoor P, Dingli D, Hayman SR, Leung N, Lust J, McCurdy A, Russell SJ, Zeldenrust SR, Kyle RA, Rajkumar SV (2014) Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 28:1122\u20131128. https:\/\/doi.org\/10.1038\/leu.2013.313","journal-title":"Leukemia"},{"key":"4184_CR21","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","volume":"130","author":"AS Levey","year":"1999","unstructured":"Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130:461\u2013470. https:\/\/doi.org\/10.7326\/0003-4819-130-6-199903160-00002","journal-title":"Ann Intern Med"},{"key":"4184_CR22","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1038\/leu.2015.80","volume":"29","author":"EK Mai","year":"2015","unstructured":"Mai EK, Bertsch U, D\u00fcrig J, Kunz C, Haenel M, Blau IW, Munder M, Jauch A, Schurich B, Hielscher T, Merz M, Huegle-Doerr B, Seckinger A, Hose D, Hillengass J, Raab MS, Neben K, Lindemann HW, Zeis M, Gerecke C, Schmidt-Wolf IG, Weisel K, Scheid C, Salwender H, Goldschmidt H (2015) Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma. Leukemia 29:1721\u20131729. https:\/\/doi.org\/10.1038\/leu.2015.80","journal-title":"Leukemia"},{"key":"4184_CR23","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.1182\/blood-2002-09-2955","volume":"102","author":"DG Maloney","year":"2003","unstructured":"Maloney DG, Molina AJ, Sahebi F, Stockerl-Goldstein KE, Sandmaier BM, Bensinger W, Storer B, Hegenbart U, Somlo G, Chauncey T, Bruno B, Appelbaum FR, Blume KG, Forman SJ, McSweeney P, Storb R (2003) Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 102:3447\u20133454. https:\/\/doi.org\/10.1182\/blood-2002-09-2955","journal-title":"Blood"},{"key":"4184_CR24","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.3324\/haematol.2015.124818","volume":"100","author":"MV Mateos","year":"2015","unstructured":"Mateos MV, Oriol A, Rosi\u00f1ol L, de Arriba F, Puig N, Mart\u00edn J, Mart\u00ednez-L\u00f3pez J, Echeveste MA, Sarr\u00e1 J, Ocio E, Ram\u00edrez G, Mart\u00ednez R, Palomera L, Payer A, Iglesias R, de la Rubia J, Alegre A, Chinea AI, Blad\u00e9 J, Lahuerta JJ, San Miguel JF (2015) Bendamustine, bortezomib and prednisone for the treatment of patients with newly diagnosed multiple myeloma: results of a prospective phase 2 Spanish\/PETHEMA trial. Haematologica 100:1096\u20131102. https:\/\/doi.org\/10.3324\/haematol.2015.124818","journal-title":"Haematologica"},{"key":"4184_CR25","doi-asserted-by":"publisher","first-page":"5752","DOI":"10.1182\/blood-2011-05-355081","volume":"118","author":"P Moreau","year":"2011","unstructured":"Moreau P, Avet-Loiseau H, Facon T, Attal M, Tiab M, Hulin C, Doyen C, Garderet L, Randriamalala E, Araujo C, Lepeu G, Marit G, Caillot D, Escoffre M, Lioure B, Benboubker L, P\u00e9gouri\u00e9 B, Kolb B, Stoppa AM, Fuzibet JG, Decaux O, Dib M, Berthou C, Chaleteix C, Sebban C, Traull\u00e9 C, Fontan J, Wetterwald M, Lenain P, Mathiot C, Harousseau JL (2011) Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood 118:5752\u20135758. https:\/\/doi.org\/10.1182\/blood-2011-05-355081","journal-title":"Blood"},{"key":"4184_CR26","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1182\/blood-2016-01-693580","volume":"127","author":"P Moreau","year":"2016","unstructured":"Moreau P, Hulin C, Macro M, Caillot D, Chaleteix C, Roussel M, Garderet L, Royer B, Brechignac S, Tiab M, Puyade M, Escoffre M, Stoppa AM, Facon T, Pegourie B, Chaoui D, Jaccard A, Slama B, Marit G, Laribi K, Godmer P, Luycx O, Eisenmann JC, Allangba O, Dib M, Araujo C, Fontan J, Belhadj K, Wetterwald M, Dorvaux V, Fermand JP, Rodon P, Kolb B, Glaisner S, Malfuson JV, Lenain P, Biron L, Planche L, Caillon H, Avet-Loiseau H, Dejoie T, Attal M (2016) VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial. Blood 127:2569\u20132574. https:\/\/doi.org\/10.1182\/blood-2016-01-693580","journal-title":"Blood"},{"key":"4184_CR27","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","volume":"394","author":"P Moreau","year":"2019","unstructured":"Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L, B\u00e9n\u00e9 MC, Broijl A, Caillon H, Caillot D, Corre J, Delforge M, Dejoie T, Doyen C, Facon T, Sonntag C, Fontan J, Garderet L, Jie KS, Karlin L, Kuhnowski F, Lambert J, Leleu X, Lenain P, Macro M, Mathiot C, Orsini-Piocelle F, Perrot A, Stoppa AM, van de Donk NW, Wuilleme S, Zweegman S, Kolb B, Touzeau C, Roussel M, Tiab M, Marolleau JP, Meuleman N, Vekemans MC, Westerman M, Klein SK, Levin MD, Fermand JP, Escoffre-Barbe M, Eveillard JR, Garidi R, Ahmadi T, Zhuang S, Chiu C, Pei L, de Boer C, Smith E, Deraedt W, Kampfenkel T, Schecter J, Vermeulen J, Avet-Loiseau H, Sonneveld P (2019) Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet 394:29\u201338. https:\/\/doi.org\/10.1016\/S0140-6736(19)31240-1","journal-title":"Lancet"},{"issue":"23","key":"4184_CR28","doi-asserted-by":"publisher","first-page":"4119","DOI":"10.1002\/cncr.28325","volume":"119","author":"AK Nooka","year":"2013","unstructured":"Nooka AK, Kaufman JL, Behera M, Langston A, Waller EK, Flowers CR, Gleason C, Boise LH, Lonial S (2013) Bortezomib-containing induction regimens in transplant-eligible myeloma patients: a meta-analysis of phase 3 randomized clinical trials. Cancer 119(23):4119\u20134128. https:\/\/doi.org\/10.1002\/cncr.28325","journal-title":"Cancer"},{"key":"4184_CR30","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1007\/s00432-015-1984-4","volume":"141","author":"W Poenisch","year":"2015","unstructured":"Poenisch W, Pl\u00f6tze M, Holzvogt B, Andrea M, Schliwa T, Zehrfeld T, Hammerschmidt D, Schwarz M, Edelmann T, Becker C, Hoffmann FA, Schwarzer A, Kreibich U, Gutsche K, Reifenrath K, Schwarzbach H, Heyn S, Franke GN, Jentzsch M, Leiblein S, Schwind S, Lange T, Vucinic V, AlAli HK, Niederwieser D (2015) Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma. J Cancer Res Clin Oncol 141:2013\u20132022. https:\/\/doi.org\/10.1007\/s00432-015-1984-4","journal-title":"J Cancer Res Clin Oncol"},{"key":"4184_CR31","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/j.1365-2141.2008.07076.x","volume":"143","author":"W P\u00f6nisch","year":"2008","unstructured":"P\u00f6nisch W, Rozanski M, Goldschmidt H, Hoffmann FA, Boldt T, Schwarzer A, Ritter U, Rohrberg R, Schwalbe E, Uhlig J, Zehrfeld T, Schirmer V, Haas A, Kreibich U, Niederwieser D, East German Study Group of Haematology and Oncology (OSHO) (2008) Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial. Br J Haematol 143:191\u2013200. https:\/\/doi.org\/10.1111\/j.1365-2141.2008.07076.x","journal-title":"Br J Haematol"},{"key":"4184_CR32","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s00432-012-1339-3","volume":"139","author":"W P\u00f6nisch","year":"2013","unstructured":"P\u00f6nisch W, Bourgeois M, Moll B, Heyn S, J\u00e4kel N, Wagner I, Rohrberg R, Hurtz HJ, Schmalfeld M, A\u00dfmann M, Edelmann T, Mohren M, Hoffmann FA, Becker C, Schwarzer A, Sch\u00f6nfelder U, Zehrfeld T, Hensel G, L\u00f6schcke K, Krahl R, Ali HA, Niederwieser D (2013) Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma. J Cancer Res Clin Oncol 139:499\u2013508. https:\/\/doi.org\/10.1007\/s00432-012-1339-3","journal-title":"J Cancer Res Clin Oncol"},{"key":"4184_CR33","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1007\/s00432-014-1737-9","volume":"140","author":"W P\u00f6nisch","year":"2014","unstructured":"P\u00f6nisch W, Holzvogt B, Pl\u00f6tze M, Andrea M, Bourgeois M, Heyn S, Zehrfeld T, Hammerschmidt D, Schwarz M, Edelmann T, Becker C, Hoffmann FA, Schwarzer A, Kreibich U, Gutsche K, Reifenrath K, Winkelmann C, Krahl R, Remane Y, Hennig E, Schliwa T, Lindner T, Kaiser T, Vucinic V, Behre G, Niederwieser D (2014) Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with newly diagnosed\/untreated multiple myeloma. J Cancer Res Clin Oncol 140:1947\u20131956. https:\/\/doi.org\/10.1007\/s00432-014-1737-9","journal-title":"J Cancer Res Clin Oncol"},{"key":"4184_CR34","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Lahuerta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BG, Miguel JF (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15:e538-548. https:\/\/doi.org\/10.1016\/S1470-2045(14)70442-5","journal-title":"Lancet Oncol"},{"key":"4184_CR1001","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3324\/haematol.2013.087585","volume":"99","author":"C Scheid","year":"2014","unstructured":"Scheid C, Sonneveld P, Schmidt-Wolf IG, van der Holt B, el Jarari L, Bertsch U, Salwender H, Zweegman S, Blau IW, Vellenga E, Weisel K, Pfreundschuh M, Jie KS, Neben K, van de Velde H, Duehrsen U, Schaafsma MR, Lindemann W, Kersten MJ, Peter N, H\u00e4nel M, Croockewit S, Martin H, Wittebol S, Bos GM, van Marwijk-Kooy M, Wijermans P, Goldschmidt H, Lokhorst HM (2014) Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65\/GMMG-HD4 trial. Haematologica. 99:148\u2013154. https:\/\/doi.org\/10.3324\/haematol.2013.087585","journal-title":"Haematologica."},{"key":"4184_CR35","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","volume":"30","author":"P Sonneveld","year":"2012","unstructured":"Sonneveld P, Schmidt-Wolf IG, van der Holt B, El Jarari L, Bertsch U, Salwender H, Zweegman S, Vellenga E, Broyl A, Blau IW, Weisel KC, Wittebol S, Bos GM, Stevens-Kroef M, Scheid C, Pfreundschuh M, Hose D, Jauch A, van der Velde H, Raymakers R, Schaafsma MR, Kersten MJ, van Marwijk-Kooy M, Duehrsen U, Lindemann W, Wijermans PW, Lokhorst HM, Goldschmidt HM (2012) Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/ GMMG-HD4 trial. J Clin Oncol 30:2946\u20132955. https:\/\/doi.org\/10.1200\/JCO.2011.39.6820","journal-title":"J Clin Oncol"},{"key":"4184_CR36","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1200\/JCO.2012.48.4626","volume":"31","author":"P Sonneveld","year":"2013","unstructured":"Sonneveld P, Goldschmidt H, Rosi\u00f1ol L, Blad\u00e9 J, Lahuerta JJ, Cavo M, Tacchetti P, Zamagni E, Attal M, Lokhorst HM, Desai A, Cakana A, Liu K, van de Velde H, Esseltine DL, Moreau P (2013) Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J Clin Oncol 31:3279\u20133287. https:\/\/doi.org\/10.1200\/JCO.2012.48.4626","journal-title":"J Clin Oncol"},{"key":"4184_CR37","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1200\/JCO.18.00685","volume":"37","author":"EA Stadtmauer","year":"2019","unstructured":"Stadtmauer EA, Pasquini MC, Blackwell B, Hari P, Bashey A, Devine S, Efebera Y, Ganguly S, Gasparetto C, Geller N, Horowitz MM, Koreth J, Knust K, Landau H, Brunstein C, McCarthy P, Nelson C, Qazilbash MH, Shah N, Vesole DH, Vij R, Vogl DT, Giralt S, Somlo G, Krishnan A (2019) Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: results of the BMT CTN 0702 Trial. J Clin Oncol 37:589\u2013597. https:\/\/doi.org\/10.1200\/JCO.18.00685","journal-title":"J Clin Oncol"},{"key":"4184_CR39","doi-asserted-by":"publisher","first-page":"e861","DOI":"10.1016\/S2352-3026(20)30323-9","volume":"12","author":"P Tacchetti","year":"2020","unstructured":"Tacchetti P, Pantani L, Patriarca F, Petrucci MT, Zamagni E, Dozza L, Galli M, Di Raimondo F, Crippa C, Boccadoro M, Barbato S, Tosi P, Narni F, Montefusco V, Testoni N, Spadano A, Terragna C, Pescosta N, Marzocchi G, Cellini C, Galieni P, GIMEMA (Gruppo ItalianoMalattieEmatologichedell\u2019Adulto Italian Myeloma Network) (2020) Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study. Lancet Haematol 12:e861\u2013e873. https:\/\/doi.org\/10.1016\/S2352-3026(20)30323-9","journal-title":"Lancet Haematol"},{"key":"4184_CR40","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1007\/s00432-017-2439-x","volume":"143","author":"H Tessenow","year":"2017","unstructured":"Tessenow H, Holzvogt M, Holzvogt B, Andrea M, Heyn S, Schliwa T, Schwarz M, Zehrfeld T, Becker C, Pfrepper C, Franke GN, Krahl R, Jentzsch M, Leiblein S, Schwind S, Bill M, Vucinic V, Lange T, Niederwieser D, P\u00f6nisch W (2017) Successful treatment of patients with newly diagnosed\/untreated light chain multiple myeloma with a combination of bendamustine, prednisone and bortezomib (BPV). J Cancer Res Clin Oncol 143:2049\u20132058. https:\/\/doi.org\/10.1007\/s00432-017-2439-x","journal-title":"J Cancer Res Clin Oncol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04184-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-022-04184-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04184-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T12:14:05Z","timestamp":1688213645000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-022-04184-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,20]]},"references-count":39,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["4184"],"URL":"http:\/\/dx.doi.org\/10.1007\/s00432-022-04184-x","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":["Cancer Research","Oncology","General Medicine"],"published":{"date-parts":[[2022,8,20]]},"assertion":[{"value":"4 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare no conflict of interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}